It would be interesting to investigate the capacity for modified exosomes to target toxic or misfolded proteins (SOD1, TDP43, FUS, dipeptide repeats) implicated in ALS by serving as conduits for new pharmacological agents or biologicals to improve therapeutic outcomes. This evidence concerns the gene FUS and amyotrophic lateral sclerosis.